Aprogen Bio CB Issuance Amendment
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2755
Risk-adjusted indicator based on 2755 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Total CB amount: 50.8 billion KRW
- • Conversion Price: 2,353 KRW/Share
- • Shares from conversion: 21,589,460 Shares
- • Dilution rate (new CB): 149.80% of current shares
- • Total potential dilution (all CBs): 319.29% of current shares
AI Analysis Summary
Aprogen Bio amended its Material Fact Report regarding the issuance of 50.8 billion KRW in private placement convertible bonds (CBs). The confirmed conversion price is 2,353 KRW per share, potentially issuing 21,589,460 new shares. This represents a significant potential dilution of 149.80% relative to the current outstanding shares from this new CB alone. When combined with existing unredeemed CBs, the total potential dilution reaches 319.29% of current shares. The funds are primarily for debt repayment (50.8 billion KRW). The high dilution rate and the use of funds for debt repayment suggest a negative impact on existing shareholder value.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.